Drug Profile
Denosumab biosimilar - PanPharmaceuticals USA
Latest Information Update: 30 Oct 2021
Price :
$50
*
At a glance
- Originator PanPharmaceuticals USA
- Class Antihypercalcaemics; Antineoplastics; Antirheumatics; Calcium regulators; Immunotherapies; Monoclonal antibodies; Osteoporosis therapies
- Mechanism of Action RANK ligand inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Discontinued Bone disorders; Bone metastases; Giant cell tumour of bone; Multiple myeloma; Osteoporosis
Most Recent Events
- 17 Jun 2015 PanPharmaceuticals USA has ceased its operations
- 16 Jun 2015 Discontinued for Bone disorders in USA (unspecified route)
- 16 Jun 2015 Discontinued for Bone metastases in USA (unspecified route)